| abstract |
This disclosure relates to antibodies that include a human antibody that specifically binds MAdCAM, preferably human MAdCAM, and functions to inhibit MAdCAM and its antigen-binding portion. This disclosure also relates to human anti-MAdCAM antibodies and their antigen-binding portions. This disclosure also relates to antibodies that are chimeric, bispecific, derived, single chain, or part of a fusion protein. This disclosure also relates to single-stranded heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. This disclosure also relates to methods of making human anti-MAdCAM antibodies, compositions comprising such antibodies, and methods of using such antibodies and compositions for diagnosis and treatment. This disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and / or light chain immunoglobulin molecules that make up the human anti-MAdCAM antibodies. The disclosure also relates to a transgenic animal or plant comprising a nucleic acid molecule of the disclosure. |